Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users
Recruiting
This study is focused on characterizing the toxic and carcinogenic potential of the Standardized Research E-cigarette (SREC) developed by the National Institute on Drug Abuse. In the environment of continuously changing e-cigarette market, SREC was developed as a model e-cigarette that will remain available for an extended period of time and can be used as a bridging element in various studies aimed at evaluating the value and limitations of e-cigarettes as tobacco risk reduction tools. Our over... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/13/2024
Locations: University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Smoking, Cigarette
Healthy Homes Study
Recruiting
This study is about home air radon testing and has two phases. The goal of the first phase is to learn about renters' and homeowners' views and plans related to radon testing. The main question this phase aims to answer is: 1. Does taking part in a focus group with information about radon testing change people's plans to test for radon? Participants in the first study phase will: * Take a survey about their views on and plans for radon testing. * Take part in a focus group discussion about r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Dartmouth Cancer Center, Lebanon, New Hampshire
Conditions: Home Air Radon Testing, Lung Cancer
Get Fit for Function
Recruiting
The purpose of this study will be to implement and evaluate a prehab program for pre-frail and frail adults who need to undergo thoracic surgery. The study team hypothesizes using an implementation framework will increase the reach, effectiveness, adoption, and implementation of the prehab program.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: Thoracic, Frailty
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
Recruiting
This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The investigators hypothesize that this drug combination will be better tolerated than current first-line chemotherapy combinations for this disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma
US National OCS Liver Perfusion (OLP) Registry
Recruiting
This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manager of the U.S. national transplant outcomes registry to obtain data that is routinely collected by the Organ Procurement and Transplantation Network (OPTN) on all transplanted organs in the U.S. for both the OCS liver transplanted patients as well as patients transplanted using o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/13/2024
Locations: University of Alabama, Birmingham, Alabama +21 locations
Conditions: Liver Transplant
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Stanford University Medical Center, Palo Alto, California +1 locations
Conditions: Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Recruiting
Nivolumab (and other agents affecting the anti-programmed death-1 \[anti-PD-1\] pathway) have demonstrated anti-tumor activity in multiple tumor types. Combinations of immune-oncology (IO) agents with complimentary mechanisms as well as radiation represent a promising strategy to improve response rates to immunotherapy and overcome resistance. In this phase I/Ib study, radiation will be used in combination with IO agents nivolumab and anti-IL-8 (BMS-986253) to assess toxicity by organ system and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: University of Chicago Medical Center, Chicago, Illinois +1 locations
Conditions: Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
HYPEROXIA Responses and ROS
Recruiting
30 participants (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy will be enrolled into this study to test the role of reactive oxygen species (ROS) in regulating cerebral blood flow (CBF). Participants can expect to be on study for 2 study visits over a 6 month period.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/13/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Cerebrovascular Disorders
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
Recruiting
In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/13/2024
Locations: VA Medical Center, Omaha, Nebraska
Conditions: Peripheral Arterial Disease
Child and Adolescent Registry for Participants With Narcolepsy
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona +24 locations
Conditions: Narcolepsy
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
Recruiting
Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Coronary Artery Disease, Atherosclerosis, Coronary Atherosclerosis of Native Coronary Artery
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Recruiting
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma